Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CNN001
MIFTS: 40

Cannabis Dependence

Categories: Mental diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Cannabis Dependence

About this section

MalaCards integrated aliases for Cannabis Dependence:

Name: Cannabis Dependence 12 74 54 15 17 71
Marijuana Abuse 43 71

Classifications:

MalaCards categories:
Anatomical: Mental diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:1849
ICD9CM 34 304.3
MeSH 43 D002189
NCIt 49 C34445
SNOMED-CT 67 85005007
ICD10 32 F12.2
UMLS 71 C0006870 C0024809
Sources

Summaries for Cannabis Dependence

About this section
Disease Ontology : 12 A drug dependence that involves the continued use of cannabis despite problems related to use of the substance.

MalaCards based summary : Cannabis Dependence, also known as marijuana abuse, is related to cocaine dependence and alcohol dependence. An important gene associated with Cannabis Dependence is CNR1 (Cannabinoid Receptor 1), and among its related pathways/superpathways is GABAergic synapse. The drugs Nicotine and Risperidone have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 74 Cannabis use disorder (CUD), also known as cannabis addiction or marijuana addiction, is defined in the... more...

Sources

Related Diseases for Cannabis Dependence

About this section

Diseases related to Cannabis Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 86)
# Related Disease Score Top Affiliating Genes
1 cocaine dependence 30.6 GABRA2 COMT CNR1
2 alcohol dependence 30.6 HCRT GABRA2 FAAH COMT CNR1
3 drug dependence 30.6 PENK GABRA2 CNR1
4 withdrawal disorder 30.3 SPICE1 PENK FAAH CNR1
5 anxiety 30.2 HCRT GABRA2 FAAH COMT CNR1
6 polysubstance abuse 30.2 FAAH COMT CNR1
7 schizophreniform disorder 30.1 NRG1 COMT CNR1
8 eating disorder 30.1 HCRT FAAH COMT CNR1
9 substance dependence 30.0 WASF2 WASF1 GABRA2 COMT CNR1
10 mental depression 29.9 WASF2 WASF1 COMT
11 substance abuse 29.9 WASF2 WASF1 GABRA2 COMT CNR1
12 major depressive disorder 29.8 HCRT COMT CNR1 ABCB1
13 avoidant personality disorder 29.7 WASF2 WASF1
14 tobacco addiction 29.7 WASF2 WASF1 GABRA2 COMT CNR1
15 alcohol use disorder 29.7 WASF2 WASF1 GABRA2 COMT
16 social phobia 29.6 WASF2 WASF1 COMT
17 dysthymic disorder 29.6 WASF2 WASF1 HCRT
18 antisocial personality disorder 29.5 WASF2 WASF1 GABRA2 COMT
19 bipolar disorder 29.1 NRG1 GABRA2 CSMD1 COMT CNR1
20 schizophrenia 28.7 NRG1 HCRT GABRA2 FAAH CSMD1 COMT
21 cannabis abuse 28.3 WASF2 WASF1 SPICE1 SPATA6 NRG1 MGLL
22 autoimmune encephalitis 10.3 HCRT FAAH CNR1
23 kleine-levin hibernation syndrome 10.3 HCRT COMT
24 pain agnosia 10.3 PENK FAAH CNR1
25 agnosia 10.3 PENK FAAH CNR1
26 opioid addiction 10.2 COMT ABCB1
27 smoking as a quantitative trait locus 3 10.2
28 personality disorder 10.2
29 depression 10.2
30 post-traumatic stress disorder 10.1 NRG1 FAAH COMT CNR1
31 conduct disorder 10.1
32 drug psychosis 10.1 SPICE1 COMT CNR1
33 drug-induced mental disorder 10.1 SPICE1 COMT CNR1
34 substance-induced psychosis 10.1 SPICE1 COMT CNR1
35 opiate dependence 10.1
36 visual epilepsy 10.0
37 seizure disorder 10.0
38 specific developmental disorder 10.0 WASF1 FAAH COMT CNR1
39 generalized anxiety disorder 10.0
40 psychotic disorder 10.0
41 severe combined immunodeficiency 10.0
42 migraine with or without aura 1 10.0 HCRT FAAH COMT CNR1
43 anorexia nervosa 10.0 HCRT COMT CNR1
44 dependent personality disorder 10.0 WASF2 WASF1
45 histrionic personality disorder 9.9 WASF2 WASF1
46 mood disorder 9.9
47 heroin dependence 9.9
48 narcissistic personality disorder 9.9 WASF2 WASF1
49 paranoid personality disorder 9.9 WASF2 WASF1
50 stroke, ischemic 9.9

Graphical network of the top 20 diseases related to Cannabis Dependence:



Diseases related to Cannabis Dependence
Sources

Symptoms & Phenotypes for Cannabis Dependence

About this section

MGI Mouse Phenotypes related to Cannabis Dependence:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.73 ABCB1 ANKFN1 CNR1 COMT CSMD1 FAAH
2 homeostasis/metabolism MP:0005376 9.4 ABCB1 CNR1 COMT CSMD1 FAAH GABRA2
Sources

Drugs & Therapeutics for Cannabis Dependence

About this section

Drugs for Cannabis Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 184)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 942 89594
2
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
3
Buspirone Approved, Investigational Phase 4 36505-84-7 2477
4
Clozapine Approved Phase 4 5786-21-0 2818
5
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
6
Topiramate Approved Phase 4 97240-79-4 5284627
7
Ondansetron Approved Phase 4 99614-02-5 4595
8
Haloperidol Approved Phase 4 52-86-8 3559
9
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
10
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
11
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
12
Polyestradiol phosphate Approved Phase 4 28014-46-2
13 Anti-Anxiety Agents Phase 4
14 Anticonvulsants Phase 4
15 Antidepressive Agents Phase 4
16 Quetiapine Fumarate Phase 4 111974-72-2
17 Antipsychotic Agents Phase 4
18 Antiemetics Phase 4
19 Gastrointestinal Agents Phase 4
20 Nicotinic Agonists Phase 4
21 Cholinergic Agents Phase 4
22 Dopamine Antagonists Phase 4
23 Serotonin Receptor Agonists Phase 4
24 Cytochrome P-450 Enzyme Inhibitors Phase 4
25 Serotonin Uptake Inhibitors Phase 4
26 Hypoglycemic Agents Phase 4
27 Dermatologic Agents Phase 4
28 Haloperidol decanoate Phase 4
29 Hydrocortisone 17-butyrate 21-propionate Phase 4
30 Hydrocortisone hemisuccinate Phase 4
31 Estradiol 17 beta-cypionate Phase 4
32 Estradiol 3-benzoate Phase 4
33 Neurotransmitter Agents Phase 4
34 Adrenergic Agents Phase 4
35 Atomoxetine Hydrochloride Phase 4
36
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
37
Dronabinol Approved, Illicit Phase 3 1972-08-3 16078
38
Lofexidine Approved, Investigational Phase 2, Phase 3 31036-80-3 30668
39
Promethazine Approved, Investigational Phase 2, Phase 3 60-87-7 4927
40
Diphenhydramine Approved, Investigational Phase 2, Phase 3 58-73-1, 147-24-0 3100
41
Zolpidem Approved Phase 2, Phase 3 82626-48-0 5732
42
Peppermint oil Approved, Investigational Phase 3 8006-90-4
43
Peppermint Approved Phase 3
44
Amphetamine Approved, Illicit, Investigational Phase 2, Phase 3 300-62-9 5826 3007
45
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
46
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
47
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
48
Vortioxetine Approved, Investigational Phase 2, Phase 3 508233-74-7 9966051
49
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
50
Clonidine Approved Phase 2, Phase 3 4205-90-7 2803

Interventional clinical trials:

(show top 50) (show all 336)
# Name Status NCT ID Phase Drugs
1 N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms Unknown status NCT03221231 Phase 4 N-acetylcysteine;Placebo Oral Tablet
2 Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine Completed NCT01153490 Phase 4
3 Clozapine for Cannabis Use Disorder in Schizophrenia Completed NCT01639872 Phase 4 Clozapine;Risperidone
4 Buspirone Treatment for Marijuana Dependence Completed NCT00875836 Phase 4 Buspirone;Placebo
5 Substance Dependent Teens - Impact of Treating Depression Study 1 Completed NCT00061113 Phase 4 Fluoxetine + outpatient cognitive behavioral therapy;fluoxetine;placebo + CBT
6 Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized Controlled Trial Completed NCT03056482 Phase 4 Ondansetron 8mg;Haloperidol 0.05mg/kg;Haloperidol 0.1mg/kg
7 Quetiapine Plus Topiramate or Placebo for Bipolar Mania & Cannabis Use in Adolescents Completed NCT00393978 Phase 4 Quetiapine and placebo;Quetiapine and Topiramate
8 Nicotine for Marijuana Withdrawal Completed NCT01400243 Phase 4 Nicotine;Placebo Patch
9 Cannabis and Schizophrenia: Effects of Clozapine Completed NCT00498550 Phase 4 Clozapine;Treatment as usual
10 Effects of Cortisol and Estradiol on the Pharmacokinetics of Tetrahydrocannabinol in Women Not yet recruiting NCT04374773 Phase 4 Dronabinol
11 An Open Label Pilot Study of Atomoxetine Hydrochloride in Adolescents With Attention Deficit/Hyperactivity Disorder and Comorbid Cannabis Abuse. Terminated NCT00687609 Phase 4 Atomoxetine
12 Evaluation of the Cognitive-behavioral Treatment Programme CANDIS in the German Outpatient Treatment Service System (CANDIS-II) Unknown status NCT00673647 Phase 3
13 Reducing Injury, ETOH and THC Use Among ED Patients Unknown status NCT00547963 Phase 2, Phase 3
14 Family and Group Therapies for Adolescent Alcohol Abuse Unknown status NCT00484367 Phase 2, Phase 3
15 A Randomized, Double-Blind, Placebo-Controlled Study of Lofexidine and Dronabinol for the Treatment of Marijuana Dependence Completed NCT01020019 Phase 2, Phase 3 Dronabinol;Placebo;Lofexidine
16 Nabilone for Cannabis Dependence: A Pilot Study Completed NCT01347762 Phase 2, Phase 3 Nabilone;Placebo
17 Achieving Cannabis Cessation: Evaluating N-Acetylcysteine Treatment (ACCENT) Completed NCT01675661 Phase 3 N-Acetylcysteine;Placebo
18 Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder Completed NCT02803229 Phase 2, Phase 3 Adderall-XR;Matched placebo
19 A Double-Blind Placebo Control Study on the Use of Nabilone for Outpatient Management of Acute Marijuana Withdrawal Completed NCT01025700 Phase 2, Phase 3 Cesemat
20 Reducing STIs in Emerging Adults Who Use Alcohol and Marijuana Completed NCT01473719 Phase 3
21 A Brief Marijuana Intervention for Adolescent Women Completed NCT00227864 Phase 3
22 The Role of Sleep in the Treatment of Cannabis Use Disorders Completed NCT01685073 Phase 2, Phase 3 Zolpidem extended-release
23 Parallel Groups Study of Divalproex Sodium (Depakote) for Irritable, Explosive Adults & Adolescents Completed NCT00218114 Phase 3 Divalproex Sodium;Placebo
24 Myorelaxant Effect of Cannabis Cream Topical Skin Application in Patients With Temporomandibular Disorders: a Randomized, Double-blind Study Completed NCT03994640 Phase 2, Phase 3
25 A Double Blind, Randomised, Three Way Crossover Study Comparing Two Different Sublingual Cannabis Based Medicine Extracts With Placebo, in Patients With Chronic Pain Due to Brachial Plexus Injury. Completed NCT01606189 Phase 3 GW-1000-02;GW-2000-02;Placebo
26 The Effect of Vaporized Cannabis on Neuropathic Pain in Spinal Cord Injury Completed NCT01555983 Phase 2, Phase 3 Vaporization of Cannabis
27 Reaching and Motivating Change in Teen Marijuana Smokers Completed NCT01109563 Phase 3
28 Vaping THC From Electronic Cigarettes: a Novel Evaluation of Intake and Pharmacokinetics Completed NCT02955329 Phase 3 Nicotine only;THC only;Nicotine and THC
29 Substance Misuse To Psychiatric Disorders for Cannabis (SToP-C)--an Early Assertive Pharmacotherapy Intervention Pilot Study Recruiting NCT03485274 Phase 2, Phase 3 Vortioxetine
30 N-Acetylcysteine for Youth Cannabis Use Disorder Recruiting NCT03055377 Phase 2, Phase 3 N-acetyl cysteine;Placebo oral capsule
31 Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity Recruiting NCT03481959 Phase 3 Methylphenidate
32 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study to Investigate the Safety and Efficacy of Cannabis Oil in Maintenance Hemodialysis Patients With Protein-energy Wasting Not yet recruiting NCT03664141 Phase 3 Cannabis oil;Placebo/ Regular Oil
33 Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia Terminated NCT01598896 Phase 2, Phase 3 Dronabinol;Clonidine;Placebo
34 CANDIS -Targeted Treatment for Cannabis Disorders Unknown status NCT00252980 Phase 2
35 Efficacy and Safety of the Hcoil Deep TMS for the Treatment of Cannabis Addiction Unknown status NCT00543036 Phase 1, Phase 2
36 Randomized and Double-blind Clinical Trial of N-acetylcysteine Versus Placebo Efficacy in the Cannabis Withdrawal Unknown status NCT01439828 Phase 2 N-acetylcystein
37 Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study Unknown status NCT02083874 Phase 2 CBD
38 A Double Blind Placebo Controlled Study of Cannabis Smoking in Inflammatory Bowel Disease Unknown status NCT01040910 Phase 1, Phase 2 smoking of cannabis;smoking cigarettes with placebo
39 The Effect of Medical Cannabis Inpatients With Palliative Pancreatic Cancer Unknown status NCT03245658 Phase 2 THC and CBD Mixture
40 Gabapentin for Cannabis Withdrawal and Use Completed NCT00395044 Phase 2 Placebo;Gabapentin
41 Gabapentin Treatment of Cannabis Dependence Completed NCT00974376 Phase 2 gabapentin 1200mg/day;Placebo
42 Open-Label Pilot Study of Quetiapine Treatment for Cannabis Dependence Completed NCT00954681 Phase 2 quetiapine
43 A Phase IIa/b, Randomised, Double-blind, Placebo-controlled, Single-site, Parallel Group Clinical Trial to Examine Cannabidiol (CBD) as a Pharmacological Treatment for Cannabis Dependence. Completed NCT02044809 Phase 2 Cannabidiol;Placebo
44 Translational Center on the Clinical Neurobiology of Cannabis Addiction Completed NCT00656487 Phase 2 rimonabant;placebo
45 A Randomized, Double-Blind, Placebo-Controlled Study of Dronabinol in the Treatment of Marijuana Addiction Completed NCT00217971 Phase 2 Dronabinol;Placebo
46 Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence Completed NCT02210195 Phase 2 aprepitant;Placebo
47 An Open-Label Trial of N-Acetylcysteine in Cannabis Dependent Adolescents Completed NCT00542750 Phase 1, Phase 2 N-Acetylcysteine
48 Pharmacological Treatment of Cannabis Withdrawal and Dependence Completed NCT01611948 Phase 2 Aprepitant;Placebo
49 A Controlled Trial of N-Acetylcysteine (NAC) in Cannabis Dependent Adolescents Completed NCT01005810 Phase 2 N-Acetylcysteine;placebo
50 A Pilot Trial of Atomoxetine to Enhance Motivational Interviewing Therapy for the Treatment of Cannabis Dependence Completed NCT00167297 Phase 2 Atomoxetine

Search NIH Clinical Center for Cannabis Dependence

Cochrane evidence based reviews: marijuana abuse

Sources

Genetic Tests for Cannabis Dependence

About this section
Sources

Anatomical Context for Cannabis Dependence

About this section

MalaCards organs/tissues related to Cannabis Dependence:

40
Brain, Testes, Eye, Lung, Cortex, Spinal Cord, Breast
Sources

Publications for Cannabis Dependence

About this section

Articles related to Cannabis Dependence:

(show top 50) (show all 794)
# Title Authors PMID Year
1
The association between cannabinoid receptor 1 gene (CNR1) and cannabis dependence symptoms in adolescents and young adults. 54 61
19443135 2009
2
Evidence for association between polymorphisms in the cannabinoid receptor 1 (CNR1) gene and cannabis dependence. 61 54
19016476 2009
3
An autosomal linkage scan for cannabis use disorders in the nicotine addiction genetics project. 54 61
18519829 2008
4
Marijuana, immunity and infection. 54 61
9610678 1998
5
What is the prevalence and risk of cannabis use disorders among people who use cannabis? a systematic review and meta-analysis. 61
32485547 2020
6
Disentangling the effects of cannabis and cigarette smoking on impulsivity. 61
32519578 2020
7
The Intersection between Spliff Usage, Tobacco Smoking, and Having the First Joint after Waking. 61
32376881 2020
8
Validation of the Australian Treatment Outcomes Profile for use in clients with cannabis dependence. 61
32129558 2020
9
Serotonin Syndrome versus Cannabis Toxicity in the Emergency Department. 61
32426664 2020
10
Coping Strategies and Factors Related to Problematic Substance Use and Behavioral Addictions Among Adolescents and Young Adults with Cancer. 61
32255742 2020
11
Impaired motor cortical plasticity associated with cannabis use disorder in young adults. 61
32323450 2020
12
Cannabis Use Disorder and Perioperative Outcomes in Major Elective Surgeries: A Retrospective Cohort Analysis. 61
31789638 2020
13
Reduced Segregation Between Cognitive and Emotional Processes in Cannabis Dependence. 61
31211388 2020
14
Personality disorders and social support in cannabis dependence: A comparison with alcohol dependence. 61
31957689 2020
15
Cannabis-dependent adolescents show differences in global reward-associated network topology: A functional connectomics approach. 61
30957353 2020
16
Psychotic disorders hospitalizations associated with cannabis abuse or dependence: A nationwide big data analysis. 61
31808250 2020
17
Impaired cognitive performance under psychosocial stress in cannabis-dependent men is associated with attenuated precuneus activity 61
31509368 2020
18
An exploratory study of cannabis use pattern and treatment seeking in patients attending an addiction treatment facility. 61
32382173 2020
19
Cannabis Dependence or Abuse in Kidney Transplantation: Implications for Posttransplant Outcomes: Erratum. 61
32106206 2020
20
Does Cannabis Dependence Add on to the Neurocognitive Impairment Among Patients With Opioid Dependence? A Cross-Sectional Comparative Study. 61
31951069 2020
21
Comments on "Relative efficacy of N-Acetylcystiene and Baclofen in cannabis dependence - A retrospective study with telephonic follow-up". 61
32382191 2020
22
Probability and correlates of transition from cannabis use to DSM-5 cannabis use disorder: Results from a large-scale nationally representative study. 61
31916333 2020
23
Medical cannabis for chronic pain: can it make a difference in pain management? 61
31535218 2020
24
Endocannabinoid genetic variation enhances vulnerability to THC reward in adolescent female mice. 61
32095523 2020
25
Exploratory analysis of genetic variants influencing molecular traits in cerebral cortex of suicide completers. 61
31418530 2020
26
Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents. 61
31375922 2020
27
Clinical Significance and Outcomes in Trial of Nabiximols for Treatment of Cannabis Dependence. 61
31904784 2020
28
Clinical Significance and Outcomes in Trial of Nabiximols for Treatment of Cannabis Dependence. 61
31904785 2020
29
Clinical Significance and Outcomes in Trial of Nabiximols for Treatment of Cannabis Dependence-Reply. 61
31904790 2020
30
Neuroanatomical alterations in people with high and low cannabis dependence. 61
31298035 2020
31
[Why and how keep in mind cannabis in our smoking outpatients?] 61
30598304 2020
32
Brain-Derived Neurotrophic Factor and Oxidative Stress in Cannabis Dependence. 61
31779002 2020
33
Problems with defining cannabis dependence. 61
31634166 2020
34
Is Recovery from Cannabis Dependence Possible? Factors that Help or Hinder Recovery in a National Sample of Canadians with a History of Cannabis Dependence. 61
32351740 2020
35
Influence of the type of childhood violence on cannabis abuse and dependence among adolescents: a systematic review and meta-analysis. 61
30627731 2020
36
Older Adults Driving Under the Influence: Associations With Marijuana Use, Marijuana Use Disorder, and Risk Perceptions. 61
29199501 2019
37
Cannabis use disorder among people using cannabis daily/almost daily in the United States, 2002-2016. 61
31698323 2019
38
Cannabis use among women of reproductive age in the United States: 2002-2017. 61
31421581 2019
39
Cortical surface morphology in long-term cannabis users: A multi-site MRI study. 61
30558823 2019
40
Modes of cannabis use: A secondary analysis of an intensive longitudinal natural history study. 61
31326775 2019
41
Brain structural changes in cannabis dependence: association with MAGL. 61
31695165 2019
42
Cannabis Dependence or Abuse in Kidney Transplantation: One Perspective. 61
30747855 2019
43
Cannabis Dependence or Abuse in Kidney Transplantation: Implications for Posttransplant Outcomes. 61
30747847 2019
44
Cannabis use disorders among adults in the United States during a time of increasing use of cannabis. 61
31586809 2019
45
"Side Effects" Observed Within ~1-90 Days After Cannabis Onset: Epidemiological Estimates for the United States, 2004-2014. 61
31487092 2019
46
Synergistic effects of marijuana abuse and HIV infection on neural activation during a cognitive interference task. 61
30239074 2019
47
Characterising heterogeneity in the use of different cannabis products: latent class analysis with 55 000 people who use cannabis and associations with severity of cannabis dependence. 61
31607281 2019
48
Cannabis Use Disorder and Post-Deployment Suicide Attempts in Iraq/Afghanistan-Era Veterans. 61
29952737 2019
49
Cannabis use and Associated Health Problems – What’s the Harm? 61
31651130 2019
50
Reward, Control & Decision-Making in Cannabis Use Disorder: Insights from Functional MRI. 61
31364398 2019
Sources

Variations for Cannabis Dependence

About this section
Sources

Expression for Cannabis Dependence

About this section
Search GEO for disease gene expression data for Cannabis Dependence.
Sources

Pathways for Cannabis Dependence

About this section

Pathways related to Cannabis Dependence according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
GABAergic synapse 36
Show member pathways
 11.44 MGLL GABRA2 FAAH CNR1
Sources

GO Terms for Cannabis Dependence

About this section

Cellular components related to Cannabis Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 postsynapse GO:0098794 9.5 WASF1 HCRT GABRA2
2 synapse GO:0045202 9.43 WASF2 WASF1 NRG1 HCRT GABRA2 CNR1
3 GABA-ergic synapse GO:0098982 9.33 NRG1 GABRA2 CNR1
4 SCAR complex GO:0031209 9.26 WASF2 WASF1
5 axon GO:0030424 9.02 PENK NRG1 GABRA2 COMT CNR1

Biological processes related to Cannabis Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Rac protein signal transduction GO:0016601 9.32 WASF2 WASF1
2 startle response GO:0001964 9.26 PENK CSMD1
3 positive regulation of Arp2/3 complex-mediated actin nucleation GO:2000601 9.16 WASF2 WASF1
4 monoacylglycerol catabolic process GO:0052651 8.96 MGLL FAAH
5 lamellipodium morphogenesis GO:0072673 8.62 WASF2 WASF1

Molecular functions related to Cannabis Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase A regulatory subunit binding GO:0034237 9.26 WASF2 WASF1
2 protein kinase A binding GO:0051018 9.16 WASF2 WASF1
3 Arp2/3 complex binding GO:0071933 8.96 WASF2 WASF1
4 acylglycerol lipase activity GO:0047372 8.62 MGLL FAAH
Sources

Sources for Cannabis Dependence

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....